Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
Risks for all-cause mortality, adverse cardiovascular events, acute kidney injury, and adverse kidney events lower versus GLP-1 RA
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.